Turnstone

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Administration, Head, TIL, Colorectal cancer, Immunotherapy, HNSCC, Takeda Oncology, Selection, Patient, G&A, Melanoma, TILS, Investment, CRC, Breast cancer, SITC, Research and development, Research institute, Turnstone, Uveal melanoma

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
  • Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
  • Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
  • Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Friday, November 10, 2023
Uveal melanoma, Selection, Colorectal cancer, Investment, Breast cancer, Administration, Patient, Piper Sandler Companies, Melanoma, Immunotherapy, Takeda Oncology, Conference, IPO, SITC, R, Research and development, Coronavirus Scientific Advisory Board, Physician, TIL, Research institute, Pharmaceutical industry, Turnstone

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Key Points: 
  • In October 2023, Turnstone appointed Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.
  • In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share.
  • Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2023, cash, cash equivalents and short-term investments were $109.1 million.
  • Net Loss: Net loss for the three months ended September 30, 2023, was $17.3 million, compared to net loss of $16.2 million for the third quarter of 2022.

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Neoplasm, Colon, Breast, Stomach, Somatic mutation, RNA, Society for Immunotherapy of Cancer, CRISPR, TIL, SITC, Immunotherapy, Selection, Annual general meeting, Gene, Melanoma, Society, Liquid biopsy, Patient, SAN, DNA, Pharmaceutical industry, Medical imaging, Turnstone

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego, California.

Key Points: 
  • We are pleased to share the promising results presented at SITC that further highlight our differentiated approach.
  • Identifying tumor-specific neoantigens arising from somatic mutations is one of the differentiating features of Turnstone’s Selected TIL process for TIDAL-01.
  • Distinct from, yet complementary to TIDAL-01, Turnstone is developing a preclinical program associated with a next-generation direct selection process.
  • Turnstone scientists are presenting preclinical data highlighting that directly selected tumor-reactive TIL can be genetically engineered using CRISPR-Cas and demonstrate that knocking out genes of interest can potentially enhance directly selected TIL quality and function.

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Retrieved on: 
Monday, October 30, 2023
American Society of Clinical Oncology, TILS, Principal, New York University Grossman School of Medicine, NCI, Rockefeller University, Clinical Oncology, Research, TIL, Centers of Biomedical Research Excellence, NYU, Selection, Melanoma, National Cancer Institute, PCC, Patient, Veteran, SAB, SPORE, Skin cancer, SAN, United States Air Force Scientific Advisory Board, Pharmaceutical industry, Medical imaging, Turnstone, Medicine

“We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.

Key Points: 
  • “We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.
  • Weber’s work has led to groundbreaking achievements in cancer immunotherapy, and he brings unique expertise and perspective to our SAB.
  • “Turnstone is advancing a differentiated approach to TIL therapy and I am delighted to join the esteemed members of Turnstone’s SAB,” said Dr. Weber.
  • I look forward to partnering with Turnstone to deliver the next-generation of TIL therapies to underserved patient populations.”

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, September 1, 2023
Exercise, IPO, AACR, Moffitt, Investment, TIL, Cancer, American Association for Cancer Research, Uveal melanoma, Research, TILS, Takeda Oncology, Patient, Administration, Colorectal cancer, Melanoma, SAN, Glomus tumor, Research institute, Research and development, R, Breast cancer, Pharmaceutical industry, Cryptocurrency, Turnstone

The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.

Key Points: 
  • The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.
  • Cash, Cash Equivalents and Short-Term Investments: As of June 30, 2023, cash, cash equivalents and short-term investments were $49.2 million.
  • The Company expects that the combined cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second quarter of 2025.
  • Net Loss: Net loss for the three months ended June 30, 2023, was $21.5 million, compared to net income of $11.6 million for the second quarter of 2022.

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Friday, July 21, 2023
Attention, SVB Securities, TIL, Telephone, BofA Securities, Sale, Prospectus, State Street, SAN, Nicollet Mall, Security (finance), Turnstone

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the pricing of its upsized initial public offering of 6,666,667 shares of common stock at a price to the public of $12.00 per share.

Key Points: 
  • SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the pricing of its upsized initial public offering of 6,666,667 shares of common stock at a price to the public of $12.00 per share.
  • The gross proceeds to Turnstone from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turnstone, are expected to be $80.0 million.
  • In addition, Turnstone has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities.

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

Retrieved on: 
Tuesday, November 29, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, NCI, TIL, National Cancer Institute, TILS, Lymphocyte, Patient, CRADA, Potyvirus, Neoplasm, Selection, Cancer, NIH, Cooperative research and development agreement, Development, Immunotherapy, Pharmaceutical industry, Vaccine, Medical imaging, Turnstone

The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.

Key Points: 
  • The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.
  • I believe TIL therapy is one of the most exciting areas of modern research in the cancer arena, notes Dr. Abbot.
  • Turnstones combination strategies with TIL and viral immunotherapy are designed to improve TIL harvest and overcome the immunosuppressive tumor microenvironment for better trafficking and expansion of our Selected TILs.
  • Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Tuesday, November 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Annual general meeting, Society, CRC, Immunotherapy, TILS, SITC, Society for Immunotherapy of Cancer, FACS, 2021 Essex County Council election, TIL, Selection, H. Lee Moffitt Cancer Center & Research Institute, Interkom Kom Ind, Turnstone, Technology, Pharmaceutical industry, Medical imaging

TIDAL-01, Turnstones lead TIL therapy candidate, focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the limitations of current TIL-based therapies.

Key Points: 
  • TIDAL-01, Turnstones lead TIL therapy candidate, focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the limitations of current TIL-based therapies.
  • Our preclinical datasets demonstrate greater promise for our Selected TILs compared to conventional TIL-based therapies to target a broader range of solid tumors.
  • The Companys lead Selected TIL therapy candidate, TIDAL-01, is expected to initiate clinical trials in 2022.
  • Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors

Retrieved on: 
Monday, October 31, 2022
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Breast cancer, Safety, Food, TILS, Colorectal cancer, Selection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Trial of the century, TIL, H. Lee Moffitt Cancer Center & Research Institute, FDA, IND, Technology, Neoplasm, Pharmaceutical industry, Medical imaging, Turnstone

Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) for Turnstones lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.

Key Points: 
  • Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) for Turnstones lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.
  • Turnstone is expected to commence a multi-site Phase 1 clinical trial later this year that will evaluate its safety and anti-tumor activity.
  • Clearance of our IND is a critical milestone for Turnstone in the advancement of our novel TIL therapy pipeline, said Sammy Farah, Ph.D., M.B.A., President and Chief Executive Officer, Turnstone Biologics.
  • Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering a differentiated approach with a clinically validated technology, tumor infiltrating lymphocyte (TIL) therapy.

Hoosiers for Good signs summer class of 11 IU basketball athletes to make an impact for six additional Indiana charity partners

Retrieved on: 
Wednesday, August 3, 2022
Other Philanthropy, Sports, University, Philanthropy, Education, Fund Raising, Basketball, Foundation, Good, Autism, Disability, IU, Development, Athlete, Feel Good Inc., Social media, High-functioning autism, Partnership, Awareness, Toy, Public relations, Turnstone

In April, Hoosiers For Good signed its inaugural spring class of 14 IU athletes, who are already making an impact for their eight Indiana charity partners .

Key Points: 
  • In April, Hoosiers For Good signed its inaugural spring class of 14 IU athletes, who are already making an impact for their eight Indiana charity partners .
  • Indiana Wish , whose mission is to help Indiana children diagnosed with life-threatening illnesses to create lasting memories, saw a 500 percent jump in social media engagement after partnering with IU basketball athletes McKenzie Holmes and Grace Berger.
  • These basketball athletes have a significant reach, Tyler Harris, Executive Director of Hoosiers For Good, said.
  • Our goal in signing this group as a team is to coordinate efforts and even further amplify the mission of charity partners.